Trial · NCT01067521
Results by group52
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 52
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression | Early Start: GA 40 mg / GA 40 mg | 0.331 | Standard Error 0.028 | confirmed relapses | |
| Total Number of Confirmed Relapses During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression | Delayed Start: Placebo / GA 40 mg | 0.505 | Standard Error 0.049 | confirmed relapses | |
| The Cumulative Number of New/Enlarging T2 Lesions Taken at Month 6 and Month 12 During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression | Early Start: GA 40 mg / GA 40 mg | 3.650 | Standard Error 0.259 | lesions | |
| The Cumulative Number of New/Enlarging T2 Lesions Taken at Month 6 and Month 12 During the Placebo Controlled (PC) Treatment Period Estimated by Negative Binomial Regression | Delayed Start: Placebo / GA 40 mg | 5.592 | Standard Error 0.490 | lesions | |
| The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Month 6 and Month 12 of the Placebo-Controlled (PC) Treatment Period Estimated by Negative Binomial Regression | Early Start: GA 40 mg / GA 40 mg | 0.905 | Standard Error 0.087 | lesions | |
| The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Month 6 and Month 12 of the Placebo-Controlled (PC) Treatment Period Estimated by Negative Binomial Regression | Delayed Start: Placebo / GA 40 mg | 1.639 | Standard Error 0.194 | lesions | |
| Brain Atrophy As Defined by the Percent of Change in Normalized Brain Volume From Baseline to Month 12 During the Placebo Controlled (PC) Treatment Period | Early Start: GA 40 mg / GA 40 mg | -0.706 | Standard Error 0.037 | percentage change | |
| Brain Atrophy As Defined by the Percent of Change in Normalized Brain Volume From Baseline to Month 12 During the Placebo Controlled (PC) Treatment Period | Delayed Start: Placebo / GA 40 mg | -0.645 | Standard Error 0.047 | percentage change | |
| Annualized Rate of Confirmed Relapses Comparing Early Starters to Delayed Starters Estimated by Negative Binomial Regression | Early Start: GA 40 mg / GA 40 mg | 0.2621 | Standard Error 0.0189 | relapses per year | |
| Annualized Rate of Confirmed Relapses Comparing Early Starters to Delayed Starters Estimated by Negative Binomial Regression | Delayed Start: Placebo / GA 40 mg | 0.3146 | Standard Error 0.0279 | relapses per year | |
| The Number of New/Enlarging T2 Lesions at Months 6, 12 and 36 Estimated by Negative Binomial Regression | Early Start: GA 40 mg / GA 40 mg | Month 6 | 2.872 | Standard Error 0.214 | lesions |
| The Number of New/Enlarging T2 Lesions at Months 6, 12 and 36 Estimated by Negative Binomial Regression | Delayed Start: Placebo / GA 40 mg | Month 6 | 3.902 | Standard Error 0.43 | lesions |
| The Number of New/Enlarging T2 Lesions at Months 6, 12 and 36 Estimated by Negative Binomial Regression | Early Start: GA 40 mg / GA 40 mg | Month 12 | 4.484 | Standard Error 0.318 | lesions |
| The Number of New/Enlarging T2 Lesions at Months 6, 12 and 36 Estimated by Negative Binomial Regression | Delayed Start: Placebo / GA 40 mg | Month 12 | 7.086 | Standard Error 0.699 | lesions |
| The Number of New/Enlarging T2 Lesions at Months 6, 12 and 36 Estimated by Negative Binomial Regression | Early Start: GA 40 mg / GA 40 mg | Month 36 | 5.836 | Standard Error 0.41 | lesions |
| The Number of New/Enlarging T2 Lesions at Months 6, 12 and 36 Estimated by Negative Binomial Regression | Delayed Start: Placebo / GA 40 mg | Month 36 | 8.759 | Standard Error 0.82 | lesions |
| The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Months 6, 12 and 36 Estimated by Negative Binomial Regression | Early Start: GA 40 mg / GA 40 mg | Month 6 | 0.629 | Standard Error 0.072 | lesions |
| The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Months 6, 12 and 36 Estimated by Negative Binomial Regression | Delayed Start: Placebo / GA 40 mg | Month 6 | 1.131 | Standard Error 9.186 | lesions |
| The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Months 6, 12 and 36 Estimated by Negative Binomial Regression | Early Start: GA 40 mg / GA 40 mg | Month 12 | 1.054 | Standard Error 0.115 | lesions |
| The Cumulative Number of Gadolinium (Gd)-Enhanced Lesions on T1-Weighted Images At Months 6, 12 and 36 Estimated by Negative Binomial Regression | Delayed Start: Placebo / GA 40 mg | Month 12 | 2.051 | Standard Error 0.282 | lesions |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01067521/results